Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United Sta
Patients with MM with 1 to 3 prior LOTs experienced high economic burden largely attributable to MM-related treatment, highlighting the need for more cost-effective therapies.
Authors
- Sundar Jagannath (ORCID: https://orcid.org/0000-0003-2934-6518)
- Akshay Kharat (ORCID: https://orcid.org/0000-0002-1056-9466)
- Eric Chinaeke (ORCID: https://orcid.org/0000-0002-8287-0012)
- Alex Z. Fu (ORCID: https://orcid.org/0000-0002-4020-6519)
- Zaina P. Qureshi (ORCID: https://orcid.org/0000-0001-9605-3980)
- Matthew Perciavalle (ORCID: https://orcid.org/0000-0003-4572-9906)
Institutions
- Janssen (Belgium) (BE)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- 490 BioTech (United States) (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1080/13696998.2025.2583668
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00